Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY
· Real-Time Price · USD
0.62
-0.02 (-3.20%)
At close: Jun 17, 2025, 10:47 AM
-3.20% (1D)
| Bid | 0.6 |
| Market Cap | 55.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.71M |
| EPS (ttm) | -0.29 |
| PE Ratio (ttm) | -2.14 |
| Forward PE | -1.51 |
| Analyst | Buy |
| Ask | 0.74 |
| Volume | 431,202 |
| Avg. Volume (20D) | 638,600 |
| Open | 0.65 |
| Previous Close | 0.64 |
| Day's Range | 0.59 - 0.67 |
| 52-Week Range | 0.33 - 1.53 |
| Beta | 1.19 |
About ONCY
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ONCY
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ONCY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 days ago
+34.1%
Oncolytics Biotech shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago
+24.56%
Oncolytics Biotech shares are trading higher after the company secured up to $20 million in flexible funding for the development of Pelareorep through a share purchase agreement with Alumin Capital.
